Canine IL-4 Biotinylated Antibody
Canine IL-4 Biotinylated Antibody Summary
His25-His132
Accession # AAD11563
Complete Your Research
Complete Your Experiment
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-4
Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13 kDa - 18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1 - 3). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four alpha -helix structure (5). Canine IL-4 is synthesized with a 24 amino acid (aa) signal sequence. Mature canine IL-4 shares 81%, 61%, 46%, 38%, and 37% aa sequence identity with feline, bovine, human, mouse, and rat IL-4, respectively. IL-4 exerts its effects through two receptor complexes (6, 7). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 R alpha and the common gamma chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and -21). The type II receptor on non‑hematopoietic cells consists of IL-4 R alpha and IL-13 R alpha 1. The type II receptor also transduces IL-13 mediated signals. IL-4 is primarily expressed by Th2-biased CD4+ T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgE in B cells, acquisition of the Th2 phenotype by naïve CD4+ T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (8 - 11). IL-4 plays a dominant role in the development of allergic inflammation and asthma (10, 12).
- Benczik, M. and S.L. Gaffen (2004) Immunol. Invest. 33:109.
- Chomarat, P. and J. Banchereau (1998) Int. Rev. Immunol. 17:1.
- Khatlani, T. et al. (1999) J. Vet. Med. Sci. 61:967.
- van der Kaaij, S.Y. et al. (1999) Immunogenetics 49:142.
- Redfield, C. et al. (1991) Biochemistry 30:11029.
- Mueller, T.D. et al. (2002) Biochim. Biophys. Acta 1592:237.
- Nelms, K. et al. (1999) Annu. Rev. Immunol. 17:701.
- Paludan, S.R. (1998) Scand. J. Immunol. 48:459.
- Corthay, A. (2006) Scand. J. Immunol. 64:93.
- Ryan, J.J. et al. (2007) Crit. Rev. Immunol. 27:15.
- Grone, A. (2002) Vet. Immunol. Immunopathol. 88:1.
- Rosenberg, H.F. et al. (2007) J. Allergy Clin. Immunol. 119:1303.
Product Datasheets
Citations for Canine IL-4 Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
6
Citations: Showing 1 - 6
Filter your results:
Filter by:
-
Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs
PLoS Negl Trop Dis, 2016;10(5):e0004614.
Species: Canine
Sample Types: Cell Culture Supernates
Applications: ELISA Development (Detection) -
Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge
PLoS ONE, 2016;11(8):e0161169.
Species: Canine
Sample Types: Cell Culture Supernates
Applications: ELISA Development (Detection) -
One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis.
Authors: Costa-Pereira C, Moreira M, Soares R, Marteleto B, Ribeiro V, Franca-Dias M, Cardoso L, Viana K, Giunchetti R, Martins-Filho O, Araujo M
BMC Vet Res, 2015;11(0):92.
Species: Canine
Sample Types: Cell Culture Supernates
Applications: ELISA Development (Detection) -
Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Authors: Lemesre JL, Holzmuller P, Goncalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G
Vaccine, 2007;25(21):4223-34.
Species: Canine
Sample Types: Cell Culture Supernates
Applications: ELISA Development -
Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs.
Authors: Fujiwara RT, Loukas A, Mendez S, Williamson AL, Bueno LL, Wang Y, Samuel A, Zhan B, Bottazzi ME, Hotez PJ, Bethony JM
Vaccine, 2005;24(4):501-9.
Species: Canine
Sample Types: Cell Culture Supernates
Applications: ELISA Development -
Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
Authors: Lemesre JL, Holzmuller P, Cavaleyra M, Goncalves RB, Hottin G, Papierok G
Vaccine, 2005;23(22):2825-40.
Species: Canine
Sample Types: Cell Culture Supernates
Applications: ELISA Development
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsIsotype Controls
Reconstitution Buffers
Staining Reagents
Supplemental Cell Selection Products
Supplemental ELISA Products
Reviews for Canine IL-4 Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Canine IL-4 Biotinylated Antibody and earn rewards!
Have you used Canine IL-4 Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
